ArticleChemistry & biodiversity2026
Unveiling the Anticancer Potential of Verbascum aydogdui: Isolation, Characterization, and In Vitro Studies.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic activity-guided fractionation of the ethanolic extract of Verbascum aydogdui, an endemic halophyte plant to Türkiye, resulted in the isolation of 16 secondary metabolites, including eight triterpene saponins, mulleinsaponins III (1), ilwensisaponin A (2), buddlejasaponin I (3), mulleinsaponin IV (4), ilwensisaponins D (5), ilwensisaponin C (6), craniosaponin A (7) and buddlejasaponin Ia (8), six iridoid glycosides, aucubine (9), eurostoside (10), geniposidic acid (11), nigroside III (13), 6-O-β-D-glucopyranosylaucubine (12), 6-O-[3-O-(E-feruloyl)-α-L-rhamnopyranosyl]-aucubine (14), and two phenylethanoid glycosides, verbascoside (15) and alyssonoside (16). Compounds 1-5 displayed significant cytotoxicity against PC3, HEPG2, HGC27, A375, MCF7, and SW480 cancer cell lines with half-maximal inhibitory concentration values of 17.6-85.1 µM, being 2 and 3 the most cytotoxic ones. Thus, 2 and 3 were further assayed for their cell death mechanisms, including apoptosis and necrosis. Compound 2 exerted anti-cancer effects in all cancer cell lines tested, except for MCF7, especially via inducing apoptosis. Its apoptotic activity was predominantly mediated by a significant increase in p53 and p21 expressions in all cancer lines tested, but for SW480. This is the first bioactivity and phytochemical study on V. aydogdui. Our results indicated that 2 could be a potential anticancer natural product that merits further in vitro and in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.